Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2004 May;5(5):411-5.

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

Author information

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7131, Rockville, MD 20852, USA.


Studies have shown that epidermal growth factor receptor (EGFR) signaling is important to normal development and neoplastic transformation, and that EGFR inhibition reduces cancer cell proliferation. The promising response rates of the EGFR inhibitor gefitinib in patients with chemotherapy-refractory non-small cell lung cancer (NSCLC) led to its approval for clinical use. However, there was little understanding of why gefitinib was effective in only some NSCLC patients. Two recent studies have identified somatic mutations in EGFR that confer its sensitivity to gefitinib in vitro and correlate strongly with patients' clinical response to the inhibitor.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center